Summary: NLS Pharmaceutics has shared preclinical findings on its dual orexin receptor agonist (DOXA) platform, which targets both orexin receptors (OX1R and OX2R) and cathepsins, offering a novel approach for treating narcolepsy and potentially other neurological disorders. The … [Read more...]
Jazz to Highlight Narcolepsy and IH Research at AAN 2024
Summary: Jazz Prescribed drugs will existing five abstracts at the 76th Once-a-year American Academy of Neurology Conference in Denver that aim on narcolepsy and idiopathic hypersomnia. Essential conclusions include things like a authentic-planet promises evaluation demonstrating … [Read more...]